Gilead quad HIV pill Stribild OK'd in US; priced 33% premium to Atripla
This article was originally published in Scrip
Executive Summary
The US FDA gave Gilead Sciences the go-ahead to market its fixed-dose, four-in-one, once-daily pill Stribild (emtricitabine, tenofovir disoproxil fumarate, evitegravir and cobicsta) as a therapy for HIV-1 infection in treatment-naïve adults.